OBJECTIVES: MRSA-B is associated with high morbidity and cost. Guidelines recommend alternative treatment when VAN MICs are >2. DAP effectiveness in MRSA-B patients (pts) with elevated VAN MICs is an important real-world question. This analysis evaluates outcomes relevant to pts and institutions including clinical success, DAP-related length of stay (LOS), and infection-related readmission. METHODS: All pts with MRSA-B were identified in CORE 2010, a retrospective, multicenter, observational registry of staphylococcal bacteremia pts with VAN MIC≥2 mg/L per local lab. Investigators assessed pt outcome (cured, improved, failed, nonevaluable) at the end or at last contact of DAP therapy. Pt characteristics and outcomes are based on the efficacy population. All pts were included in the safety analysis.  RESULTS: A total of 158 pts with MRSA-B were identified; 142 had initial VAN MIC=2 and were evaluable for outcome: 47% male, 40% >65 years, 27% CrCl <30mL/min, 21% on dialysis, 22% treated in the ICU.  Frequent concurrent infections included skin and skin structure (12%), endocarditis (9%), bone/joint (8%). Median (min,max) DAP dose and duration were 6 mg/kg (4,11) and 13.5 days (2,62), respectively.  80% (114/142) received prior antibiotics; (88% of which was VAN). Success occurred in 89% overall, with no difference between first (89% [25/28]) and second-line (89% [101/114]) DAP treatment. Time to clinical response ranged from 1-27 days (median=2). Median (min,max) DAP-related LOS was 9 days (2,44). 21 pts (15%) were evaluated in the ER within 60 days of completing DAP therapy.  Infection-related readmission occurred in 10 pts (7%). 7 pts experienced 9 AEs possibly related to DAP; 5 pts discontinued DAP due to AE. Overall mortality rate was 12%; 4 pts died within ≤7 days.  CONCLUSIONS: This evaluation of real-world effectiveness demonstrates that DAP may be a useful agent for MRSA-B isolates with a VAN MIC=2.  Additional comparative effectiveness and resource utilization studies are warranted.